Login to Your Account

Biotech Firms Turn to Reverse Mergers in Slow IPO Market

By Catherine Hollingsworth

Monday, March 17, 2008
With the initial public offering market slowing, many private biotech companies are going the reverse merger route, seeking to combine their operations with either public companies that have fallen on hard times or public shells to gain access to capital markets. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription